Especially in recent years, MUC1 neoantigens has been proven as a tumor-associated antigen highly expressed on many adenocarcinomas (breast, colon, lung, kidney, ovary, etc.), and MUC1 neoantigens has been successfully utilized in immunotherapeutic approaches for the development of peptide-, carbohydrate-, DNA-, and dendritic cell (DC)-based vaccines [33], and clinical trials (NCT00415818 [34] and NCT00409188 [35]) in lung cancer. The gene discussed is MUC1; the disease is adenocarcinoma.